Lithuanian-French scientific cooperation in Horizon Europe: IMC experience

Eiva Bernotiene, MD, PhD

Head of Department of Regenerative Medicine, Chief Researcher, IMC

20 10 2021, Vilnius



State Research Institute
Center of Innovative Medicine





Development of Adipose Tissue Derived Stem Cell (ADSC) Therapy for Osteoarthritis *ADIPOA*

EC FP7 large scale international collaborative project (Grant No. 241719) 2010-2014

Project budget:

12 124 769 €

Centre of Innovative

Medicine budget:

944 368 €

COORDINATOR <u>Prof. Christian Jorgensen</u>, Centre Hospilaire Universitaire de Montpellier, INSERM,France

Daniele Noel, INSERM, France

PARTNERS:

Philippe Bourin, Etablissement Français du Sang, Toulouse, France

Louis Casteilla, INSERM, CNRS, Université Toulouse III, France

Other PARTNERS: universities and research centers from Ireland, Italy, Germany, Netherlands, Israel and Lithuania (IMC; leader dr. Eiva Bernotienė)

Osteoartritis – articular disease assotiated with cartilage degeneration and leading to disability. Aim of the study – to implement ADSC based cellular therapy.








Development of Adipose Tissue Derived Stem Cell (ADSC) Therapy for Osteoarthritis *ADIPOA*




EC FP7 ADIPOA large scale international collaborative project (Grant No. 241719)

Investigation scheme IMC

<u>Department of</u>
<u>Regenerative Medicine:</u>
Cocultures of human
patient joint tissues with
ADSC – crosstalk?





<u>Conclusions – ADSC:</u>

- ➤ Safe for therapeutic application;
- ➤ Chondroprotective effects
- ✓ also under inflammation;
- ➤ Stimulate cartilage reparation.

Clinical trial phase I:

✓ EMA permission



Autologous adipose derived stem cell therapy: ADIPOA2 phase 2 trial



H2020-SC1-2017 Grant Agreement number: 732163 Coordination CHU Montpellier

- A phase IIb, multi-centre, prospective, randomized, double-blind study, comparing culture-expanded autologous ADSC with placebo
- 3 arms to a total of 153 patients and followed up for 25 months (1 month before and 24 months after knee injection)
- Duration of recruitment for each centre: 12 months


Treatment group	Dose	Frequency	Number of patients
Group 1	2.10 ⁶ ADSC	Single injection	51
Group 2	10.10 ⁶ ADSC	Single injection	51
Group 3	Vehicle	Single injection	51

Euronanomed 3: Proposal Evospine II stage of evaluation


Stem cell-based technologies for intervertebral disc degeneration

COORDINATOR <u>Prof. Christian</u>
<u>Jorgensen</u>, CHU de Montpellier,
Danièle Noël; INSERM, France
PARTNERS: other universities and
research centers from France,
Spain, Belgium and Lithuania
(IMC; leader dr. Eiva Bernotiene)

Anatomy of the healthy spine



Intervertebral Disc Degeneration





ElectroMechanoActive Polymer-based Scaffolds for Heart-on-Chip, 2021-2025

Coordinator: Dr. Christian Bergaud; Centre National de la Recherche Scientifique CNRS (CNRS) France; other partners from Hungary Germany Switzerland Portugal Germany Spain Czeck and Lithuania Leader of IMC partner Dr. E.Bernotienė


Total budget 5.356.096 €; IMC Partner 748.753 €

Advancing the Understanding and Treatment of Heart Diseases

Horizon 2020 Call: H2020-NMBP-TR-IND-2018-2020 (TRANSFORMING EUROPEAN INDUSTRY)

The primary goal of the project is to achieve clinically relevant cardiac models for early-stage cardiovascular drug screening.





ElectroMechanoActive Polymer-based Scaffolds for Heart-on-Chip, 2021-2025


Development of platform for growth and maturation of cardiac microtissues

biomimetic 3D microenvironment that provides all the needed stimuli will be developed:

- > electrical,
- > mechanical,
- ➤ biochemical (release of active molecules)

Role of IMC:

- ✓ evaluation of human iPSC-derived cardiomyocyte maturation on the scaffolds
- √healthy and diseased states
- ✓ responses to drugs









Acknowledgements

Inserm

de la santé et de la recherche médicale





ÉTABLISSEMENT FRANÇAIS DU SANG

















